A10BD08 - Metformin and Vildagliptin |
Propably not porphyrinogenic |
PNP |
Rationale
Neither metformin nor vildagliptin have the potential to inhibit or induce CYP enzymes. No porphyrinogenic physiological effects. Vomiting and loss of appetite is potentially porphyrogenic side effects through interference with nutrition and motivates attendance.
Chemical description
Metformin is a biguanide anti-diabetic. Vildagliptine is a hydroxyadmantane pyrrolidine carbonitrile anti-diabetic.
Therapeutic characteristics
Metformin and vildagliptin are indicated for the improvement of glycaemic control in adult patients with type 2 diabetes mellitus. Vomiting and loss of appetite are potentially porphyrogenic side effects through interference with nutrition intake.
Metabolism and pharmakokinetics
Neither metformin nor vildagliptin are metabolized via CYP enzymes.
References
- Scientific articles
- Golightly LK, Drayna CC, et al. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012 Aug 1;51(8):501-14. #1126
- He YL. Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharmacokinet. 2012 Mar 1;51(3):147-62. PMID 22339447. #1127
- Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010 Aug; 12(8):648-58. PMID 20590741. #1114
- Tornio A, Niemi M, et al. Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. Trends Pharmacol Sci. 2012 Jun;33(6):312-22. PMID 22475684. #4358
- Summary of Product Characteristics
- The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Eucreas. #3004
- Other sources
- See also the monographs of metformin (ATC A10BA02) and of vildagliptin (ATC A10BH02). #3005
Similar drugs
© NAPOS 2024